RIGL - RIGEL PHARMACEUTICALS INC

28.87
-0.650   -2.251%

Share volume: 354,349
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$29.52
-0.65
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
40%
Profitability 25%
Dept financing 31%
Liquidity 50%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-12.57%
1 Month
-16.10%
3 Months
-33.48%
6 Months
-29.36%
1 Year
47.82%
2 Year
1,738.85%
Key data
Stock price
$28.87
P/E Ratio 
N/A
DAY RANGE
$28.24 - $29.20
EPS 
$20.42
52 WEEK RANGE
$15.50 - $52.24
52 WEEK CHANGE
$47.82
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
18.473 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
3.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$529,553
AVERAGE 30 VOLUME 
$368,823
Company detail
CEO: Raul R. Rodriguez
Region: US
Website: rigel.com
Employees: 160
IPO year: 2000
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Rigel Pharmaceuticals, Inc. discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the. treatment of warm autoimmune hemolytic anemia.

Recent news